Lipid-based nanoparticles containing cationic derivatives of PTA (1,3,5-triaza-7-phosphaadamantane) as innovative vehicle for Pt complexes: Production, characterization and in vitro studies

Bergamini, 2012, Platinum and ruthenium complexes of new long-tail derivatives of PTA (1,3,5-triaza-7-phosphaadamantane): synthesis, characterization and antiproliferative activity on human tumoral cell lines, Inorg. Chim. Acta, 391, 231, 10.1016/j.ica.2012.04.031 Bergamini, 2013, New PTA (1,3,5-triaza 7-phosphaadamantane) derivatives associating zwitterionic structure and coordinative ability, Inorg. Chim. Acta, 398, 11, 10.1016/j.ica.2012.12.006 Bravo, 2010, Coordination chemistry of 1,3,5-triaza-7-phosphaadamantane (PTA) and derivatives. Part II. The quest for tailored ligands, complexes and related applications, Coord. Chem. Rev., 254, 555, 10.1016/j.ccr.2009.08.006 Casini, 2008, Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds, J. Med. Chem., 51, 6773, 10.1021/jm8006678 Cortesi, 1996, Effect of cationic liposome composition on their in vitro citotoxicity and protective effect on carried DNA, Int. J. Pharm., 139, 69, 10.1016/0378-5173(96)04574-7 Cortesi, 2012, Long-chain cationic derivatives of PTA (1,3,5-triaza-7-phosphaadamantane) as new components of potential non-viral vectors, Int. J. Pharm., 431, 176, 10.1016/j.ijpharm.2012.04.014 Cortesi, 2014, Cationic lipid nanosystems as carriers for nucleic acids, New Biotechnol., 31, 44, 10.1016/j.nbt.2013.10.001 Daigle, 1974, Synthesis of a monphosphorus analog of hexamethylenetetramine, J. Heterocycl. Chem., 11, 407, 10.1002/jhet.5570110326 Daigle, 1998, 1,3,5-Triaza-7-phosphatricyclo[3.3.1.13,7]decane and derivatives, Inorg. Synth., 32, 40, 10.1002/9780470132630.ch6 Doktorovová, 2014, Cationic solid lipid nanoparticles interfere with the activity of antioxidant enzymes in hepatocellular carcinoma cells, Int. J. Pharm., 471, 18, 10.1016/j.ijpharm.2014.05.011 Esposito, 2008, Solid lipid nanoparticles as delivery systems for bromocriptine, Pharm. Res., 25, 1521, 10.1007/s11095-007-9514-y Esposito, 2015, Biodistribution of nanostructured lipid carriers: a tomographic study, Eur. J. Pharm. Biopharm., 89, 145, 10.1016/j.ejpb.2014.12.006 Galvao, 2014, Unexpected low-dose toxicity of the universal solvent DMSO, FASEB J., 28, 1, 10.1096/fj.13-235440 García-Moreno, 2014, Gold(I) complexes with alkylated PTA (1,3,5-triaza-7-phosphaadamantane) phosphanes as anticancer metallodrugs, Eur. J. Med. Chem., 79, 164, 10.1016/j.ejmech.2014.04.001 Gasco, M.R., Gasco, P., Bernareggi A. 2008. Nanoparticle formulations of Platinum compounds, US Pat., 0038 371 A1. Godwin, 1992, High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis, Proc. Natl. Acad. Sci. U. S. A., 89, 3070, 10.1073/pnas.89.7.3070 Hall, 2014, Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes, Cancer Res., 74, 3913, 10.1158/0008-5472.CAN-14-0247 Hansen, 1989, Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill, J. Immunol. Methods, 119, 203, 10.1016/0022-1759(89)90397-9 Heydenreich, 2003, Preparation and purification of cationic solid lipid nanospheres – effects on particle size, physical stability and cell toxicity, Int. J. Pharm., 254, 83, 10.1016/S0378-5173(02)00688-9 Joshi, 2009, Lipid nanoparticles for parenteral delivery of actives, Eur. J. Pharm. Biopharm., 71, 161, 10.1016/j.ejpb.2008.09.003 Kaur, 2013, Solid lipid nanoparticles: tuneable anti-cancer gene/drug delivery systems Kelava, 2011, Biological actions of drug solvents, Period. Biol., 113, 311 Lin, 2013, Squalene-containing nanostructured lipid carriers promote percutaneous absorption and hair follicle targeting of diphencyprone for treating alopecia areata, Pharm. Res., 30, 435, 10.1007/s11095-012-0888-0 Lv, 2006, Toxicity of cationic lipids and cationic polymers in gene delivery, J. Control. Release, 114, 100, 10.1016/j.jconrel.2006.04.014 Lozzio, 1975, Human chronic myelogeneous leukemia cell line with positive Philadelphia chromosome, Blood, 45, 321, 10.1182/blood.V45.3.321.321 Mistry, 1992, Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine) platinum(IV) (JM221) in human ovarian carcinoma cell lines, Cancer Res., 52, 6188 Muller, 1996, Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles, Int. J. Pharm., 138, 85, 10.1016/0378-5173(96)04539-5 Muller, 1997, Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant, Pharm. Res., 14, 458, 10.1023/A:1012043315093 Olbrich, 2001, Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA, J. Control. Release, 77, 345, 10.1016/S0168-3659(01)00506-5 Phillips, 2004, Coordination chemistry of 1,3,5-triaza-7-phosphaadamantane (PTA): transition metal complexes and related catalytic, medicinal and photoluminescent applications, Coord. Chem. Rev., 248, 955, 10.1016/j.ccr.2004.03.010 Schubert, 2005, Characterization of surface-modified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier, Eur. J. Pharm. Biopharm., 61, 77, 10.1016/j.ejpb.2005.03.006 Svilenov, 2014, Solid lipid nanoparticles—a promising drug delivery system, 187 Soussan, 2009, Drug delivery by soft matter: matrix and vesicular, Angew. Chem. Int. Ed., 48, 274, 10.1002/anie.200802453 Souto, 2010, Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs, Curr. Eye Res., 35, 537, 10.3109/02713681003760168 Sternberg, 1994, New structures in complex formation between DNA and cationic liposomes visualized by freeze-fracture electron microscopy, FEBS Lett., 356, 361, 10.1016/0014-5793(94)01315-2 Tabatt, 2004, Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticles-mediated gene transfer, Eur. J. Pharm. Biopharm., 57, 155, 10.1016/j.ejpb.2003.10.015 Vighi, 2012, Design flexibility influencing the in vitro behavior of cationic SLN as a nonviral gene vector, Int. J. Pharm., 12, 10 Wheate, 2003, Multi-nuclear platinum complexes as anti-cancer drugs, Coord. Chem. Rev., 241, 133, 10.1016/S0010-8545(03)00050-X